Kringle Pharma: Announcements of individual stock's financial estimates revision for September 2024 period.
Kringle Pharma: Regarding the revision of the third quarter financial results and financial estimates for the September 2024 period.
Kringle Pharma: September 2024 fiscal third quarter financial results announcement (Japanese standards) (non-consolidated)
KRINGLE PHARMA: Q&A session on financial results briefing for the 2nd quarter of the fiscal year ending September 2024
KRINGLE PHARMA: Financial results briefing materials for the 2nd quarter of the fiscal year ending 2024/9
KRINGLE PHARMA: Summary of financial results for the 2nd quarter of the fiscal year ending September 2024 [Japanese GAAP] (unconsolidated)
KRINGLE PHARMA: Quarterly Report - 23rd Quarter 2nd Quarter (2024/01/01 to 2024/03/31)
KRINGLE PHARMA: Confirmation letter
Kringle Pharma: Confirmation
Kringle Pharma: Quarterly Report - 23rd Quarter 1st Quarter (2023/10/01 - 2023/12/31)
Kringle Pharma: Explanatory materials on the top line data for the acute phase III trial of spinal cord injury and financial results for the 1st quarter of the fiscal year ending 2024/9
Kringle Pharma: Summary of financial results for the 1st quarter of the fiscal year ending September 2024 [Japanese GAAP] (unconsolidated)
Kringle Pharma: Extraordinary Report
Kringle Pharma: Confirmation letter
Kringle Pharma: Securities Report — 22nd Term (2022/10/01 - 2023/09/30)
Kringle Pharma: Questions and answers on the full-year financial results briefing for the fiscal year ending September 2023
Kringle Pharma: Full year financial results briefing materials for the fiscal year ending September 2023
Kringle Pharma: Brief Financial Report for the Fiscal Year Ending September 2023 [Japanese GAAP] (unconsolidated)
Kringle Pharma: Funding through financial results for the 3rd quarter of the fiscal year ending September 2023 and the 13th issue of stock acquisition rights
Kringle Pharma: Confirmation letter
No Data